TIP25-243: Randomized Study Evaluating Optimal Dose, Efficacy and Safety of E7386 + Lenvatinib Versus Treatment of Physicians' Choice in Advance/Recurrent Endometrial Carcinoma Previously Treated With Anti-PD-(L)1 Immunotherapy

Ramez Eskander; Jung Yun Lee; Mansoor Mirza; Domenica Lorusso; Helen Mackay; Isabelle Ray-Coquard; Ana Oaknin; Antonio Gonzalez-Martin; Kosei Hasegawa; Bradley Corr; Xiaohua Wu; Alexandra Leary; Tianle Hu; Lea Dutta; Chinyere Okpara; Jodi McKenzie; Vicky Makker

doi:10.6004/jnccn.2024.7252

TIP25-243: Randomized Study Evaluating Optimal Dose, Efficacy and Safety of E7386 + Lenvatinib Versus Treatment of Physicians' Choice in Advance/Recurrent Endometrial Carcinoma Previously Treated With Anti-PD-(L)1 Immunotherapy

Ramez Eskander, Jung Yun Lee, Mansoor Mirza, Domenica Lorusso, Helen Mackay, Isabelle Ray-Coquard, Ana Oaknin, Antonio Gonzalez-Martin, Kosei Hasegawa, Bradley Corr, Xiaohua Wu, Alexandra Leary, Tianle Hu, Lea Dutta, Chinyere Okpara, Jodi McKenzie, Vicky Makker

Résultats de recherche: Contribution à un journal › Article › Revue par des pairs

langue originale	Anglais
journal	JNCCN Journal of the National Comprehensive Cancer Network
Volume	23
Numéro de publication	35
Les DOIs	https://doi.org/10.6004/jnccn.2024.7252
état	Publié - 28 mars 2025

Accès au document

10.6004/jnccn.2024.7252

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

Eskander, R., Lee, J. Y., Mirza, M., Lorusso, D., Mackay, H., Ray-Coquard, I., Oaknin, A., Gonzalez-Martin, A., Hasegawa, K., Corr, B., Wu, X., Leary, A., Hu, T., Dutta, L., Okpara, C., McKenzie, J., & Makker, V. (2025). TIP25-243: Randomized Study Evaluating Optimal Dose, Efficacy and Safety of E7386 + Lenvatinib Versus Treatment of Physicians' Choice in Advance/Recurrent Endometrial Carcinoma Previously Treated With Anti-PD-(L)1 Immunotherapy. JNCCN Journal of the National Comprehensive Cancer Network, 23(35). https://doi.org/10.6004/jnccn.2024.7252

Eskander, Ramez ; Lee, Jung Yun ; Mirza, Mansoor et al. / TIP25-243 : Randomized Study Evaluating Optimal Dose, Efficacy and Safety of E7386 + Lenvatinib Versus Treatment of Physicians' Choice in Advance/Recurrent Endometrial Carcinoma Previously Treated With Anti-PD-(L)1 Immunotherapy. Dans: JNCCN Journal of the National Comprehensive Cancer Network. 2025 ; Vol 23, Numéro 35.

@article{a0c831298eaf4f78a18f0111d352f6ae,

title = "TIP25-243: Randomized Study Evaluating Optimal Dose, Efficacy and Safety of E7386 + Lenvatinib Versus Treatment of Physicians' Choice in Advance/Recurrent Endometrial Carcinoma Previously Treated With Anti-PD-(L)1 Immunotherapy",

author = "Ramez Eskander and Lee, {Jung Yun} and Mansoor Mirza and Domenica Lorusso and Helen Mackay and Isabelle Ray-Coquard and Ana Oaknin and Antonio Gonzalez-Martin and Kosei Hasegawa and Bradley Corr and Xiaohua Wu and Alexandra Leary and Tianle Hu and Lea Dutta and Chinyere Okpara and Jodi McKenzie and Vicky Makker",

year = "2025",

month = mar,

day = "28",

doi = "10.6004/jnccn.2024.7252",

language = "English",

volume = "23",

journal = "JNCCN Journal of the National Comprehensive Cancer Network",

issn = "1540-1405",

number = "35",

}

Eskander, R, Lee, JY, Mirza, M, Lorusso, D, Mackay, H, Ray-Coquard, I, Oaknin, A, Gonzalez-Martin, A, Hasegawa, K, Corr, B, Wu, X, Leary, A, Hu, T, Dutta, L, Okpara, C, McKenzie, J & Makker, V 2025, 'TIP25-243: Randomized Study Evaluating Optimal Dose, Efficacy and Safety of E7386 + Lenvatinib Versus Treatment of Physicians' Choice in Advance/Recurrent Endometrial Carcinoma Previously Treated With Anti-PD-(L)1 Immunotherapy', JNCCN Journal of the National Comprehensive Cancer Network, VOL. 23, Numéro 35. https://doi.org/10.6004/jnccn.2024.7252

TIP25-243: Randomized Study Evaluating Optimal Dose, Efficacy and Safety of E7386 + Lenvatinib Versus Treatment of Physicians' Choice in Advance/Recurrent Endometrial Carcinoma Previously Treated With Anti-PD-(L)1 Immunotherapy. / Eskander, Ramez; Lee, Jung Yun; Mirza, Mansoor et al.
Dans: JNCCN Journal of the National Comprehensive Cancer Network, Vol 23, Numéro 35, 28.03.2025.

Résultats de recherche: Contribution à un journal › Article › Revue par des pairs

TY - JOUR

T1 - TIP25-243

T2 - Randomized Study Evaluating Optimal Dose, Efficacy and Safety of E7386 + Lenvatinib Versus Treatment of Physicians' Choice in Advance/Recurrent Endometrial Carcinoma Previously Treated With Anti-PD-(L)1 Immunotherapy

AU - Eskander, Ramez

AU - Lee, Jung Yun

AU - Mirza, Mansoor

AU - Lorusso, Domenica

AU - Mackay, Helen

AU - Ray-Coquard, Isabelle

AU - Oaknin, Ana

AU - Gonzalez-Martin, Antonio

AU - Hasegawa, Kosei

AU - Corr, Bradley

AU - Wu, Xiaohua

AU - Leary, Alexandra

AU - Hu, Tianle

AU - Dutta, Lea

AU - Okpara, Chinyere

AU - McKenzie, Jodi

AU - Makker, Vicky

PY - 2025/3/28

Y1 - 2025/3/28

UR - http://www.scopus.com/inward/record.url?scp=105002542959&partnerID=8YFLogxK

U2 - 10.6004/jnccn.2024.7252

DO - 10.6004/jnccn.2024.7252

M3 - Article

C2 - 40157347

AN - SCOPUS:105002542959

SN - 1540-1405

VL - 23

JO - JNCCN Journal of the National Comprehensive Cancer Network

JF - JNCCN Journal of the National Comprehensive Cancer Network

IS - 35

ER -

Eskander R, Lee JY, Mirza M, Lorusso D, Mackay H, Ray-Coquard I et al. TIP25-243: Randomized Study Evaluating Optimal Dose, Efficacy and Safety of E7386 + Lenvatinib Versus Treatment of Physicians' Choice in Advance/Recurrent Endometrial Carcinoma Previously Treated With Anti-PD-(L)1 Immunotherapy. JNCCN Journal of the National Comprehensive Cancer Network. 2025 mars 28;23(35). doi: 10.6004/jnccn.2024.7252